Stephen L. Sabba

This profile gathers the share dealings of Stephen L. Sabba across 2 companies, led by Ligand Pharmaceuticals Inc and QLT Inc/BC. Over a trading history stretching from 4 August 2008 to 23 March 2026, the count stands at 49 filings.

Market trades split into 3 purchases (€85k) and 11 sales (€5.3M). Taken together, the sales exceed the purchases by €5.2M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 20 share grants and 13 option exercises. Since January 2026: no purchases and 2 sales on the market.

In size, the median ticket on the buying side is €8,642. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 100% of cases, with a median move of +37.9%. Past outcomes like these are no guarantee of what comes next.

Most recently, on 25 March 2026, the filings show an open-market sale worth €180k in Ligand Pharmaceuticals Inc. The most recent open-market purchase was published on 14 October 2014, 4,408 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.